Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Descriptive
Fundamental
Technical
ETF
All
Exchange Index Sector Industry Country
Market Cap. Dividend Yield Float Short Analyst Recom. Option/Short
Earnings Date Average Volume Relative Volume Current Volume Trades
Price Target Price IPO Date Shares Outstanding Float
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 200 Total
ZNTL - Zentalis Pharmaceuticals Inc - Stock Price Chart
TickerZNTL [NASD, RUT]
CompanyZentalis Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap293.98MEPS (ttm)-3.36
P/E-EPS this Y39.51%
Forward P/E-EPS next Y-34.28%
PEG-EPS past 5Y-50.05%
P/S7.25EPS next 5Y-
P/B0.64EPS Q/Q113.26%
Dividend-Sales Q/Q-
Insider Own12.31%Inst Own113.65%
Insider Trans-0.48%Inst Trans-0.93%
Short Float28.13%EarningsMay 07/b
Analyst Recom2.20Target Price12.11
Avg Volume653.22K52W Range8.25 - 30.53
Jun-18-24Downgrade Wells Fargo Overweight → Equal Weight
Jun-18-24Downgrade Wedbush Neutral → Underperform $15 → $4
Jun-18-24Downgrade Morgan Stanley Overweight → Equal-Weight $38 → $8
Jun-18-24Downgrade Jefferies Buy → Hold $42 → $6
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gallagher CamPresident, Interim CFOMay 31 '24Sale11.989,597114,972633,680May 31 06:27 PM
HAUSMAN DIANAChief Medical OfficerMay 09 '24Sale12.623,35642,353373,876May 09 07:46 PM
Epperly Melissa B,Chief Financial OfficerFeb 12 '24Sale11.442,57329,435451,449Feb 12 08:22 PM
Gallagher CamPresidentFeb 12 '24Sale11.441,17313,419643,277Feb 12 08:21 PM
Gallagher CamPresidentFeb 02 '24Sale11.5411,552133,310644,450Feb 05 07:13 PM
AWIN - AERWINS Technologies Inc - Stock Price Chart
TickerAWIN [NASD]
CompanyAERWINS Technologies Inc
CountryUSA
IndustryScientific & Technical Instruments
Market Cap1.60MEPS (ttm)-9.07
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S1.26EPS next 5Y-
P/B-EPS Q/Q407.08%
Dividend-Sales Q/Q-
Insider Own21.91%Inst Own1.09%
Insider Trans0.00%Inst Trans-20.28%
Short Float13.85%Earnings-
Analyst Recom1.00Target Price100.00
Avg Volume1.16M52W Range2.12 - 74.40
AERWINS Technologies, Inc. engages in the development and manufacture of technologies to enable air mobility. It also provides centralized operating system for managing open sky, hoverbikes, drones, shared computing services, blockchain verification, and AI algorithm generation services. The company was founded in 2017 and is headquartered in Los Angeles, CA.
THMO - ThermoGenesis Holdings Inc - Stock Price Chart
TickerTHMO [NASD]
CompanyThermoGenesis Holdings Inc
CountryUSA
IndustryMedical Devices
Market Cap1.75MEPS (ttm)-4.75
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y62.10%
P/S0.18EPS next 5Y-
P/B1.79EPS Q/Q88.67%
Dividend-Sales Q/Q6.42%
Insider Own55.83%Inst Own2.24%
Insider Trans0.00%Inst Trans-48.53%
Short Float0.61%Earnings-
Analyst Recom1.00Target Price5.00
Avg Volume85.78K52W Range0.30 - 1.82
ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, CAR-Txpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Xu XiaochunCEONov 17 '23Sale1.02600,000612,000327,121Nov 21 07:30 AM
HOLO - MicroCloud Hologram Inc - Stock Price Chart
TickerHOLO [NASD]
CompanyMicroCloud Hologram Inc
CountryChina
IndustryElectronic Components
Market Cap5.61MEPS (ttm)-1.45
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-483.40%
P/S0.19EPS next 5Y-
P/B0.28EPS Q/Q-320.24%
Dividend-Sales Q/Q-
Insider Own69.53%Inst Own1.20%
Insider Trans0.00%Inst Trans-98.39%
Short Float66.66%Earnings-
Analyst Recom-Target Price-
Avg Volume12.72M52W Range1.17 - 113.00
MicroCloud Hologram, Inc. engages in research, development, and application of holographic technology. It operates through the Holographic Solutions and Holographic Technology Service segments. The company was founded in 2020 and is headquartered in New York, NY.
BFRG - Bullfrog AI Holdings Inc - Stock Price Chart
TickerBFRG [NASD]
CompanyBullfrog AI Holdings Inc
CountryUSA
IndustryHealth Information Services
Market Cap15.54MEPS (ttm)-0.92
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S222.04EPS next 5Y-
P/B2.28EPS Q/Q5.91%
Dividend-Sales Q/Q-
Insider Own58.77%Inst Own2.15%
Insider Trans-2.64%Inst Trans-
Short Float2.80%Earnings-
Analyst Recom-Target Price-
Avg Volume81.31K52W Range2.35 - 8.35
BullFrog AI Holdings, Inc. is a digital biopharmaceutical company, which engages in artificial intelligence and machine learning driven analysis of complex data sets in medicine and healthcare. The company was founded by Vininder Singh in August 2017 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Singh VininderChief Executive OfficerApr 02 '24Sale2.916,94420,1762,542,446Apr 03 05:09 PM
Singh VininderChief Executive OfficerApr 01 '24Sale2.9943,056128,6472,549,390Apr 03 05:09 PM
Singh VininderChief Executive OfficerJan 22 '24Sale7.5025,000187,5002,597,294Jan 22 08:41 PM
Singh VininderChief Executive OfficerJan 17 '24Sale3.184,84815,4402,642,446Jan 18 10:10 AM
Singh VininderChief Executive OfficerJan 16 '24Sale2.558,51621,7412,647,294Jan 18 10:10 AM
CING - Cingulate Inc - Stock Price Chart
TickerCING [NASD]
CompanyCingulate Inc
CountryUSA
IndustryBiotechnology
Market Cap3.55MEPS (ttm)-23.91
P/E-EPS this Y92.08%
Forward P/E-EPS next Y-13.35%
PEG-EPS past 5Y-24.19%
P/S-EPS next 5Y-
P/B0.89EPS Q/Q91.51%
Dividend-Sales Q/Q-
Insider Own25.37%Inst Own1.89%
Insider Trans0.00%Inst Trans-73.16%
Short Float6.00%EarningsMay 08/b
Analyst Recom2.00Target Price20.00
Avg Volume216.28K52W Range0.65 - 21.20
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Werth Peter J.DirectorApr 11 '24Option Exercise0.001,036,0087531,175,925Apr 12 09:47 PM
Callahan Jennifer L.Corporate ControllerSep 15 '23Buy0.675,0003,34845,508Sep 18 06:00 PM
Werth Peter J.DirectorAug 11 '23Buy0.551,823,1551,000,0012,798,320Aug 14 04:38 PM
ARBB - ARB IOT Group Ltd - Stock Price Chart
TickerARBB [NASD]
CompanyARB IOT Group Ltd
CountryMalaysia
IndustryInformation Technology Services
Market Cap13.48MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own43.11%Inst Own0.00%
Insider Trans0.00%Inst Trans-
Short Float0.28%Earnings-
Analyst Recom1.00Target Price3.00
Avg Volume71.09K52W Range0.58 - 4.80
ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Kuala Lumpur, Malaysia.
SLRX - Salarius Pharmaceuticals Inc - Stock Price Chart
TickerSLRX [NASD]
CompanySalarius Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap-EPS (ttm)-173.74
P/E-EPS this Y-597.92%
Forward P/E-EPS next Y12.31%
PEG-EPS past 5Y64.97%
P/S-EPS next 5Y-
P/B0.06EPS Q/Q81.69%
Dividend-Sales Q/Q-
Insider Own6.08%Inst Own-
Insider Trans0.00%Inst Trans-3.23%
Short Float-EarningsMay 09
Analyst Recom3.00Target Price26.00
Avg Volume17.87K52W Range3.09 - 12.48
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
CABA - Cabaletta Bio Inc - Stock Price Chart
TickerCABA [NASD, RUT]
CompanyCabaletta Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap403.14MEPS (ttm)-1.72
P/E-EPS this Y-29.17%
Forward P/E-EPS next Y-3.98%
PEG-EPS past 5Y-26.63%
P/S-EPS next 5Y-
P/B1.82EPS Q/Q-13.60%
Dividend-Sales Q/Q-
Insider Own13.60%Inst Own100.71%
Insider Trans-0.33%Inst Trans-19.25%
Short Float22.71%EarningsMay 15/b
Analyst Recom1.00Target Price33.56
Avg Volume1.22M52W Range9.25 - 26.35
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Binder GwendolynSee RemarksJan 19 '24Option Exercise1.0111,00011,11031,000Jan 19 06:30 PM
Binder GwendolynSee RemarksJan 19 '24Sale19.5911,000215,43920,000Jan 19 06:30 PM
Binder GwendolynSee RemarksDec 19 '23Option Exercise1.0111,00011,11031,000Dec 19 08:37 PM
Binder GwendolynSee RemarksDec 19 '23Sale21.8911,000240,78920,000Dec 19 08:37 PM
Binder GwendolynSee RemarksNov 20 '23Option Exercise1.0111,00011,11031,000Nov 21 04:30 PM
AMIX - Autonomix Medical Inc. - Stock Price Chart
TickerAMIX [NASD]
CompanyAutonomix Medical Inc.
CountryUSA
IndustryMedical Devices
Market Cap21.04MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B2.77EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own56.40%Inst Own0.18%
Insider Trans0.00%Inst Trans-
Short Float0.72%Earnings-
Analyst Recom-Target Price-
Avg Volume61.75K52W Range1.13 - 7.60
Jun-18-24 08:00AM Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial (GlobeNewswire) -17.04%
Jun-17-24 04:05PM Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer (GlobeNewswire) -7.53%
Jun-10-24 08:00AM Autonomix to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024 (GlobeNewswire) -9.49%
Jun-06-24 09:00AM This One Company Is Working On A Breakthrough Approach To Revolutionize Pain Management (News Direct) -9.09%
Jun-03-24 02:52PM AMIX Stock Earnings: Autonomix Medical Reported Results for Q4 2024 (InvestorPlace) -10.53%
08:15AM Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial (GlobeNewswire)
May-31-24 08:05AM Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +7.55%
May-23-24 09:15AM Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer (GlobeNewswire) -5.91%
May-14-24 04:15PM Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire)
Apr-25-24 08:30AM Autonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary Microchip (GlobeNewswire) +6.84%
Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. The company was founded by Robert Schwartz, Landy Toth, David A. Robins, and Robert A. Van Tassel on June 10, 2014 and is headquartered in Doylestown, PA.
1234561020